Features Of The Pathogenesis And Correction Of Anemia Induced By Antiviral Therapy For Hepatitis C
Abstract
HCV infection remains one of the leading problems in the diagnosis and treatment of chronic liver disease, given the scale of hepatitis C virus infection worldwide, the significant number of unexamined but at-risk patients, and the incidence of cirrhosis and liver cancer. Anemia is the most common hematological adverse event, which in turn significantly reduces the quality of life of patients during antiviral therapy, their adherence to treatment, and increases the risk of developing cardiovascular, renal and cerebral disorders.
Similar Articles
-
Comparative Analysis Of The Results Of The Endoscopic Treatment Of Gastroduodenal Ulcerative Bleeding
The American Journal of Medical Sciences and Pharmaceutical Research: No. 04 (2021) / Dilshodbek Mamadaliyevich Khakimov, Muzaffar Madaminovich Nosirov, Bekzodbek Baxodirovich Karaboev, -
Experience Of Application Of A New Hemostatic Agent "Gemogubka" In The Prevention Of Bleeding From The Gall Bladder Body After Traditional Cholecystectomy
-
ENDOSCOPIC METHODS OF HAEMOSTASIS IN GASTRODUODENAL BLEEDING
The American Journal of Medical Sciences and Pharmaceutical Research: No. 03 (2022) / Gulomidin Minhodjievich Khodjimatov , Dilshodbek Mamadalievich Hakimov , Bekzodbek Bakhodirovich Karaboev , Khabibullo Khamdamovich Khamdamov , Nosirbek Adhamovich Kasimov, -
Comparative Analysis Of Endoscopic Methods Of Hemostasis In Bleeding From Esophageal Varicose Veins
The American Journal of Medical Sciences and Pharmaceutical Research: No. 08 (2020) / Kadirov Rustam Nodirovich, -
Comparative Characteristics Of Rheological Properties Of Blood In Combined Face Injuries Before And After Treatment
The American Journal of Medical Sciences and Pharmaceutical Research: No. 01 (2021) / Bakhtiyar Karshievich Narmurotov , Shukhrat Abdujalilovich Boymuradov , Jamolbek Abdukakhkhorovich Djuraev , -
Assessment Of Factors Of Vascular Wall Damage In Depressive Disorders In Patients With Myocardial Infarction
The American Journal of Medical Sciences and Pharmaceutical Research: No. 12 (2020) / Mukhamadieva N.B., -
inical And Laboratory Results Of Intrauterine Device Cu T 380 A Intrauterine System Intraoperative Injection
The American Journal of Medical Sciences and Pharmaceutical Research: No. 09 (2020) / Nasirova Zebiniso Azizovna, Negmadjanov Bahodur Boltaevich, -
Clinical And Functional Changes In Hard Tissues Of Teeth In Patients With Hemophilia
The American Journal of Medical Sciences and Pharmaceutical Research: No. 12 (2020) / Alisher Berdikulovich Norbutaev, Mukhiddin Kamariddinovich Shamsiev, Nodira Sharipovna Nazarova , -
Study Of The Effect Of Polysaccharides On Hemostasis
The American Journal of Medical Sciences and Pharmaceutical Research: No. 01 (2021) / Khoshimov N.N., Nasirov K.E., Raimova G.M., Musaeva M.K., Azizov V.G., Тuraev A. S., Murоdоv S.S., Inоyatоv I.I., Badirdinоv B.R., Abdusalоmоv Sh.A., -
The State Of The Prostacycline-Thromboxane System In Patients With Ischemic Heart Disease
The American Journal of Medical Sciences and Pharmaceutical Research: No. 07 (2020) / Khattahanova Rabiya Yuldashevna,,
References
Moiseev S.V., Abdurakhmanov D.T. How to improve the results of standard antiviral therapy in patients with chronic hepatitis C: the role of hematopoietic growth factors. Clinical Pharmacology and Therapy, 2011, 20 (2), P.2 [in russian]
Sulkowski M et al. EASL 2008. Abstract 991, Oral Presentation. [in russian]
Bakulin I.G., Sandler Yu.G., Sharabanov A.S. Hematological adverse events during antiviral therapy in patients with chronic hepatitis C. Hepatological Forum, 2011, 4, C.2 [in russian]
Kwo PY, Lawitz EJ, McCone J, et al. S-Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010; 376: 705–16.
Berman K, Kwo PY. Boceprevir, an NS3 protease inhibitor of HCV. Clin Liver Dis 2009; 13: 429–39.
Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195–206.
Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previ- ously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405–16.
www.anemia.ru
Sulkowski M.S., Shiffman M.L., Afdhal N.H. et al. Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate. Gastroenterology, 2010,139, 1602-16011
McHutchinson J., Lawitz E., Shiffman M.L. et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N. Engl. J. Med., 2009, 361, 580-593.
Sakamoto N., Tanaka Y. et al. ITPA gene variant protects against anemia induced by pegylated interferon-α and ribavirin therapy for Japanese pa- tients with chronic hepatitis C. Hepatology Research, 2010, 40, 1063-1071/
Hitomi Y., Cirulli E.T., Fellay J. et al. Inosine tripfosphate protects against ribavirin-induced ATP loss by restoring adenylosuccinate synthase function. Gastroenterology, 2011, 140, 1314-1321.
Bennett CL, Silver SM, Djulbegovic B, Samaras AT, Blau CA, Gleason KJ, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-asso- ciated anemia. Jama 2008, 299, 914-924.
